Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1656 in T2DM patients treated with insulin
NCT00856908Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of AZD1656 in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoint: Systolic Blood Pressure at 4 weeks. Started Feb 2009; status: completed.
02
Drugs
AZD1656
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00856908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856908.